Market Overview

UPDATE: Credit Suisse Upgrades GlaxoSmithKline to Neutral; Pricing Policy Impact Priced In

Share:
Related GSK
Oppenheimer: Buy Five Prime Therapeutics, It's Worth $45/Share
7 Trends Drug Investors Should Know
Be Ready To Get A Piece Of PayPal - Cramer's Mad Money (5/21/15) (Seeking Alpha)

Credit Suisse raised its rating on GlaxoSmithKline (NYSE: GSK) from Underperform to Neutral.

Credit Suisse noted, "We upgrade rating of GSK to NEUTRAL from Underperform and increase our target price to Rs2,055 (from Rs1,870). Our positive stance is driven by the fact that the overhang of pricing policy is largely over, in our view, and the margins (ex-pricing policy impact) have bottomed out and should rebound. Under the new pricing policy, GSK drugs are now more affordable and should gain volume share. On the current portfolio under price control (25% of sales), the pricing policy allows players to take 10% price increase after one year and GSK should benefit."

GlaxoSmithKline closed at $43.85 on Wednesday.

Latest Ratings for GSK

DateFirmActionFromTo
Jan 2015New Street ResearchDowngrades
Jul 2014MainfirstDowngradesUnderperform
Apr 2014Argus ResearchUpgradesHoldBuy

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (GSK)

Around the Web, We're Loving...

Get Benzinga's Newsletters